Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
1.650
+0.100 (6.45%)
Feb 18, 2026, 4:00 PM EST - Market closed
Invivyd Revenue
Invivyd had revenue of $13.13M in the quarter ending September 30, 2025, with 41.17% growth. This brings the company's revenue in the last twelve months to $50.04M, up 332.71% year-over-year. In the year 2024, Invivyd had annual revenue of $25.38M.
Revenue (ttm)
$50.04M
Revenue Growth
+332.71%
P/S Ratio
9.30
Revenue / Employee
$500,390
Employees
100
Market Cap
465.28M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionIVVD News
- 15 days ago - Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration - GlobeNewsWire
- 4 weeks ago - Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 - GlobeNewsWire
- 5 weeks ago - Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - GlobeNewsWire
- 2 months ago - Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - GlobeNewsWire
- 3 months ago - Invivyd to Participate at the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 3 months ago - Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness - GlobeNewsWire
- 3 months ago - Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination - Seeking Alpha